Hertl M - Search Results

1

Pemphigus: Current and Future Therapeutic Strategies.

Didona D, Maglie R, Eming R, Hertl M. Didona D, et al. Among authors: hertl m. Front Immunol. 2019 Jun 25;10:1418. doi: 10.3389/fimmu.2019.01418. eCollection 2019. Front Immunol. 2019. PMID: 31293582 Free PMC article. Review.

2

T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals.

Veldman CM, Gebhard KL, Uter W, Wassmuth R, Grötzinger J, Schultz E, Hertl M. Veldman CM, et al. Among authors: hertl m. J Immunol. 2004 Mar 15;172(6):3883-92. doi: 10.4049/jimmunol.172.6.3883. J Immunol. 2004. PMID: 15004196

3

Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris.

Veldman C, Höhne A, Dieckmann D, Schuler G, Hertl M. Veldman C, et al. Among authors: hertl m. J Immunol. 2004 May 15;172(10):6468-75. doi: 10.4049/jimmunol.172.10.6468. J Immunol. 2004. PMID: 15128839

4

Autoimmune bullous disorders.

Eming R, Hertl M; Autoimmune Diagnostics Working Group. Eming R, et al. Among authors: hertl m. Clin Chem Lab Med. 2006;44(2):144-9. doi: 10.1515/CCLM.2006.027. Clin Chem Lab Med. 2006. PMID: 16475898 Free article. Review.

5

Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.

Eming R, Rech J, Barth S, Kalden JR, Schuler G, Harrer T, Hertl M. Eming R, et al. Among authors: hertl m. Dermatology. 2006;212(2):177-87. doi: 10.1159/000090659. Dermatology. 2006. PMID: 16484825

6

T cell control in autoimmune bullous skin disorders.

Hertl M, Eming R, Veldman C. Hertl M, et al. J Clin Invest. 2006 May;116(5):1159-66. doi: 10.1172/JCI28547. J Clin Invest. 2006. PMID: 16670756 Free PMC article. Review.

7

Immunoadsorption in pemphigus.

Eming R, Hertl M. Eming R, et al. Among authors: hertl m. Autoimmunity. 2006 Nov;39(7):609-16. doi: 10.1080/08916930600972040. Autoimmunity. 2006. PMID: 17101505 Review.

8

Detection of low avidity desmoglein 3-reactive T cells in pemphigus vulgaris using HLA-DR beta 1*0402 tetramers.

Veldman C, Eming R, Wolff-Franke S, Sonderstrup G, Kwok WW, Hertl M. Veldman C, et al. Among authors: hertl m. Clin Immunol. 2007 Mar;122(3):330-7. doi: 10.1016/j.clim.2006.09.014. Epub 2006 Nov 17. Clin Immunol. 2007. PMID: 17113829

9

Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies).

Niedermeier A, Eming R, Pfütze M, Neumann CR, Happel C, Reich K, Hertl M. Niedermeier A, et al. Among authors: hertl m. Arch Dermatol. 2007 Feb;143(2):192-8. doi: 10.1001/archderm.143.2.192. Arch Dermatol. 2007. PMID: 17309999

10

Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus.

Pfütze M, Niedermeier A, Hertl M, Eming R. Pfütze M, et al. Among authors: hertl m. Eur J Dermatol. 2007 Jan-Feb;17(1):4-11. doi: 10.1684/ejd.2007.0090. Epub 2007 Feb 27. Eur J Dermatol. 2007. PMID: 17324820 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

502 results

Search Page